SynthesisFrontiers in endocrinology2026
Association of IL-6 and IL-17 with thyroid eye disease.
Synthesis in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory Signatures of Graves' Orbitopathy: Linking Thyroid Autoimmunity, Disease Activity, and Novel Hematological Biomarkers.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Thyroid Eye Disease (TED) is the most common extrathyroidal manifestation of Graves' disease. Interleukin-6 (IL-6) and interleukin-17 (IL-17) have been implicated in its pathogenesis, but individual study results remain inconsistent. However, existing findings on IL-6 and IL-17 levels in the serum or tears of TED patients remain inconsistent. Aim: This meta-analysis aimed to statistically evaluate the level of IL-6 and IL-17 in patients with TED. Methods: A systematic literature search was conducted across five electronic databases (PubMed, Web of Science, Elsevier Science Direct, Wiley Online Library, and CNKI). The search strategy targeted the terms "Thyroid Eye Disease" in conjunction with "Interleukin-6" or "Interleukin-17" in title and abstract fields. Results are presented as standardized mean differences (SMD) with 95% confidence intervals (CI). Results: This meta-analysis demonstrated significantly elevated levels of both IL-6 and IL-17 in patients with TED compared to controls. Pooled estimates showed a substantial increase in IL-6 (SMD: 1.68; 95% CI: 0.83-2.53), with substantial heterogeneity. Similarly, IL-17 levels were markedly higher in TED patients overall (SMD: 1.78; 95% CI: 1.18-2.37). Furthermore, patients with active TED exhibited significantly higher IL-6 and IL-17 levels than those with inactive disease. Conclusions: To our knowledge, this meta-analysis is a large-scale systematic evaluation of IL-6 and IL-17 levels in patients with TED. These findings describe the circulating cytokine profile in the studied population and may inform future hypothesis-driven research. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261277844, identifier CRD420261277844.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.